Table 4.

Coefficient Estimates of Interactions with Time in Analysis of eGFR over Time in Patients with Sickle Cell Disease

	HbSS/HbSβ0-Thalassemia (Severe genotypes)		HbSC/HbSβ+-Thalassemia (Mild genotypes)
	Estimate (SE)	P	Estimate (SE)	P
Hemoglobin	0.48 (0.16)	0.003	0.22 (0.30)	0.5
LDH	−0.00097 (0.00052)	0.07	−0.0056 (0.0022)	0.01
Reticulocyte count	−0.00088 (0.0023)	0.7	−0.0029 (0.0060)	0.6
Hemoglobin F	0.082 (0.056)	0.1	0.27 (0.30)	0.4
WBC count	0.095 (0.075)	0.2	0.016 (0.13)	0.9
Ferritin	−0.00044 (0.00022)	0.04	−0.00093 (0.00072)	0.2
Total bilirubin	0.18 (0.12)	0.1	0.89 (0.90)	0.3
Direct bilirubin	−1.36 (5.43)	0.8	−6.75 (16.23)	0.7
Indirect bilirubin	0.34 (0.25)	0.2	6.53 (3.42)	0.06
Baseline eGFR	0.018 (0.0082)	0.03	0.0081 (0.020)	0.7
Baseline proteinuria	−2.14 (0.91)	0.02	−1.68 (2.32)	0.5
Hemoglobinuria	−0.73 (1.04)	0.5	***	***
Urine specific gravity	63.39 (86.25)	0.5	148.50 (170.90)	0.5
Systolic BP	−0.029 (0.017)	0.08	−0.086 (0.025)	<0.001
Diastolic BP	−0.017 (0.019)	0.4	−0.11 (0.044)	0.01
Weight	0.0028 (0.017)	0.9	−0.0071 (0.023)	0.8
History of diabetes	−0.73 (1.42)	0.6	−4.25 (1.41)	0.003
History of stroke	−1.54 (0.75)	0.04	0.37 (3.51)	0.9
History of acute chest syndrome	−0.42 (0.81)	0.6	−0.23 (1.14)	0.8
History of avascular necrosis	−0.073 (0.60)	0.9	−2.13 (1.18)	0.07
History of leg ulcers	0.12 (0.65)	0.9	−0.30 (3.70)	0.9
ACEi/ARB therapy	−0.52 (0.43)	0.2	0.40 (0.72)	0.6
Hydroxyurea therapy	0.10 (0.28)	0.7	−0.26 (0.60)	0.7
Ongoing need for RBC transfusion	1.68 (1.38)	0.2	1.24 (14.42)	0.9

Estimates expressed in mL/min/1.73 m2 per year; for continuous covariates, estimate is per 1-unit increase. Results from minimally adjusted (age and sex) linear mixed effects model with random intercept and random time effect for each covariate.

ACEi = Angiotensin-converting enzyme inhibitor, ARB = angiotensin receptor blocker; RBC, _______; LDH, _____; WBC, _____; BP, blood pressure; eGFR, estimated glomerular filtration rate; SE, _____.

^***Too few patients to model.